Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
RBX2660 + RBX7455
- Development stage
- Unknown
- Lead developer
- Ferring Pharmaceuticals
- Modality
- Synthetic Biology Platforms → Engineered Microbial Therapeutics → Microbiome Therapeutics, Fresh FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Yeast Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Bacterial Strains → Single Strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Defined Consortia → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics, Frozen FMT → Fecal Microbiota Transplantation (FMT) → Microbiome Therapeutics, Genetically Modified Bacteria → Engineered Microbial Therapeutics → Microbiome Therapeutics, Microbial Metabolites → Microbiome-Derived Products → Microbiome Therapeutics, Microbial Proteins → Microbiome-Derived Products → Microbiome Therapeutics, Complex Communities → Multi-strain Products → Live Biotherapeutic Products → Microbiome Therapeutics
- Administration
- Oral, Rectal
01
Overview
RBX2660 + RBX7455 is a combination microbiota-based therapeutic regimen being evaluated for the treatment of active pediatric Crohn's disease. RBX2660 (brand name Rebyota) is a broad-spectrum, human-derived fecal microbiota suspension designed for rectal administration via colonoscope or enema. RBX7455 is a room-temperature stable, orally administered microbiota capsule formulation. Both products are developed by Rebiotix, a Ferring Pharmaceuticals company, and are classified as live biotherapeutic products. The therapy aims to restore a diverse and functional gut microbiome to counteract the dysbiosis associated with Crohn's disease, thereby modulating the host immune system and reducing intestinal inflammation. The PediCRaFT pilot study, conducted at McMaster Children's Hospital, investigates the feasibility and efficacy of an induction dose of RBX2660 followed by a six-week maintenance course of RBX7455.
- Other names
- microbiota-McMaster Children's Hospital-Crohn's diseasePediCRaFT FMTFecal Microbiota TransplantFMToral microbiota capsulesOMC
Beyond the preview
Go deeper on RBX2660 + RBX7455.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on RBX2660 + RBX7455.